GlassScriptNeuromark Radiofrequency Console
Payments companies reported to CMS as associated with Neuromark Radiofrequency Console. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Neuromark Radiofrequency Console, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Neuromark Radiofrequency Console
These are the largest totals companies reported as associated with Neuromark Radiofrequency Console. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ronald Kuppersmith | College Station, TX | Otolaryngology | $280,599.32 |
| Marc Dubin | Baltimore, MD | Otolaryngology | $205,315.10 |
| Greg Davis | Puyallup, WA | Otolaryngology | $105,550.25 |
| Richard Manes | New Haven, CT | Otolaryngology | $60,130.79 |
| Anthony Delsignore | New York, NY | Otolaryngology | $45,706.58 |
| Douglas Reh | Lutherville Timonium, MD | Otolaryngology | $34,580.89 |
| Kibwei Mckinney | Oklahoma City, OK | Otolaryngology | $33,022.34 |
| Masayoshi Takashima | Houston, TX | Otolaryngology | $31,875.51 |
| Michael Sillers | Birmingham, AL | Otolaryngology | $26,180.11 |
| Eugene Brown | Charleston, SC | Otolaryngology | $24,561.21 |
Prescribed Neuromark Radiofrequency Console?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.